Cigall Kadoch, PhD
Inaugural AACR Award for Outstanding Achievement in Basic Cancer Research

Cigall Kadoch, PhD

Assistant Professor of Pediatric Oncology, Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Institute Member and Epigenomics Program Co-director
Broad Institute of MIT and Harvard
Cambridge, Massachusetts

For her pioneering biochemical and functional characterization of normal and aberrant SWI/SNF chromatin remodeling complexes and her elucidation of the mechanisms by which the disruption of these complexes contributes to over one-fifth of human cancers.

The AACR Award for Outstanding Achievement in Basic Cancer Research was established by the AACR to recognize an early-career investigator for meritorious achievements in basic cancer research. The award is intended to recognize an individual who has not yet reached 46 years of age at the time of their award presentation.

Kadoch is world-renowned for her seminal work involving the biology of ATP-dependent chromatin remodeling complexes, which are groups of proteins that influence how DNA is packaged, thereby controlling when and how strongly genes are expressed. In a landmark study early in her career, Kadoch discovered that more than 20 percent of cancers have mutations in genes encoding proteins that are part of mammalian SWI/SNF chromatin remodeling complexes. Since then, the focus of her research has been on characterizing the role of each of the 29 potential subunits of the SWI/SNF chromatin remodeling complexes in normal tissue development and defining how mutated forms of these subunits contribute to cancer development. This work has effectively laid the foundation for new mechanistic approaches to developing anticancer therapeutics and has propelled Kadoch to launch a biomedical startup company, Foghorn Therapeutics, to further translate such discoveries from the bench to the bedside. To learn more, please visit the press release.